Osimertinib may be considered a cost-effective treatment option compared with PDC in the second-line setting in patients with EGFR-T790M mutation-positive NSCLC from a UK payer perspective. Further data from the ongoing AURA clinical trial program will reduce the inherent uncertainty in the analysis.
HAL BLFC allowed more outpatient treatment with improved recurrence detection and reduced transurethral resection of the bladder tumors, cystectomies, bed days and operating room time, with minimal cost impact across all risk groups, demonstrating the economic benefits of introducing HAL.
This study was sponsored by Galderma Laboratories. The sponsor was involved in the design of the model structure but not in the collection of the data used to populate the model. Manuscript preparation was also funded by Galderma. Taieb is an investigator and advisor for Galderma. Gold is an investigator for Galderma. Feldman is a consultant and speaker for Galderma and has received grants from Galderma. Dansk and Bertranou received a research grant from Galderma to conduct this study. Dansk and Bertranou contributed to the design of the model structure, the sourcing and inputting of the data, and the interpretation of the results. Taieb, Feldman, and Gold contributed to the interpretation of the results. All authors reviewed draft versions of the manuscript and gave permission for the submission of the final version.
A 3 4 7 -A 7 6 6 A745 since few incidences of grade 3 or higher AEs were observed at HRQOL assessment points. Results: In 380 patients with all baseline scores, total of 562 EQ-5D and 564 GHS scores were observed at 3, 6, and 12 months during the study treatment. Mean EQ-5D and GHS scores at baseline were 0.767 and 60.2, respectively. In EQ-5D analysis, G2 fatigue (−0.048), G1 and G2 mucositis (−0.068 and −0.107), G1 nausea (−0.057), G1 and G2 edema (−0.065 and −0.082), G2 motor neuropathy (−0.186), G2 sensory neuropathy (−0.084), and G2 myalgia (−0.117) were significantly (P < 0.05) associated with decreased scores. In GHS analysis, G1 and G2 fatigue (−7.6 and −7.2), G1 mucositis (−8.8), and G2 sensory neuropathy (−9.1) were significantly associated with decreased scores. ConClusions: Appropriate care for these AEs would lead to better HRQOL of patients in the target population. Model-based cost-effectiveness analysis should account for these AEs as well.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.